Merck Announces First-Quarter 2024 Financial Results : vimar

Sales Reflect Continued Strong Growth in Oncology and Vaccines



Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange,...

Related Keywords

Chicago , Illinois , United States , Canada , Japan , China , Argentina , Argentine , America , American , Adempas Verquvo , Raludotatug Deruxtecan , Robertm Davis , Gardasil , Daiichi Sankyo , Harpoon Therapeutics Inc , Instagram , European Commission Approved Merck , Alliance Revenue , Gilead Sciences Inc , World Health Organization Group , Linkedin , Animal Health , European Union , Drug Administration , Elanco Animal Health Incorporated , Twitter , Facebook , Statement Of Merck Co Inc , Net Income Attributable To Merck Co Inc , Youtube , Merck Co Inc , Imago Biosciences Inc , Merck Co , Exchange Commission , Accepted Accounting Principles , Harpoon Therapeutics , Imago Biosciences , Asia Pacific , Latin America , Companion Animal , Quarter Expense , World Health Organization , Priority Review , Biologics License Application , Opportunistic Infections , Gilead Sciences , Prescription Drug User Fee Act , First In Class Treatment , Adults With , Results From Phase , Read Announcement , Neoadjuvant Treatment , Then Continued , Adjuvant Treatment , High Risk , Primary Advanced , Recurrent Endometrial Carcinoma , Significantly Improved Overall Survival Versus , Daiichi Sankyo Initiated , Patients With Platinum Resistant Ovarian Cancer , Initiated Phase , Investigational Oral , Combination With , First Line Treatment , Certain Patients With Metastatic , Announced Positive Data , Demonstrated Immune Responses , Results From Multiple Phase , Announced Plans , Conduct Clinical Trials , Novel Investigational Multi Valent , Single Dose Regimen , Gilead Announced Phase , Lenacapavir Maintained Viral Suppression , Oncology Investor Event , American Society , Clinical Oncology Annual Meeting , Canada Toll Free , Looking Statement , Securities Litigation Reform Act , Annual Report , Human Papillomavirus Quadrivalent , Human Papillomavirus , Rubella Virus Vaccine Live , Varicella Virus Vaccine Live , Rotavirus Vaccine , Conjugate Vaccine , Before Taxes , Net Income Attributable , Income Attributable , Common Share Assuming Dilution , Shares Outstanding Assuming Dilution , Divestiture Related Costs , Tax Provision , Common Share Assuming , Total Vaccines , Total Diabetes , Includes Pharmaceutical ,